These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35074903)

  • 21. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
    Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
    J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
    Klein O; Kee D; Markman B; Michael M; Underhill C; Carlino MS; Jackett L; Lum C; Scott C; Nagrial A; Behren A; So JY; Palmer J; Cebon J
    Clin Cancer Res; 2020 Sep; 26(17):4454-4459. PubMed ID: 32532787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP; Guadarrama E; Chae YK; Dennis MJ; Powers BC; Liao CY; Ferri WA; George TJ; Sharon E; Ryan CW; Othus M; Lopez G; Blanke CD; Kurzrock R
    Cancer; 2024 Sep; 130(17):2918-2927. PubMed ID: 38358334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series.
    Konishi K; Okamoto M; Tokumitsu R; Yano M; Nasu K; Kobayashi E
    Med Mol Morphol; 2024 Jun; 57(2):83-90. PubMed ID: 38289480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis.
    Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carroll BT; Theuner J; Li S; Fu P; Kirkwood JM
    JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Rozeman EA; Hoefsmit EP; Reijers ILM; Saw RPM; Versluis JM; Krijgsman O; Dimitriadis P; Sikorska K; van de Wiel BA; Eriksson H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; Shannon K; Haanen JBAG; Stretch J; Ch'ng S; Nieweg OE; Mallo HA; Adriaansz S; Kerkhoven RM; Cornelissen S; Broeks A; Klop WMC; Zuur CL; van Houdt WJ; Peeper DS; Spillane AJ; van Akkooi ACJ; Scolyer RA; Schumacher TNM; Menzies AM; Long GV; Blank CU
    Nat Med; 2021 Feb; 27(2):256-263. PubMed ID: 33558721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
    Weber J; Mandala M; Del Vecchio M; Gogas HJ; Arance AM; Cowey CL; Dalle S; Schenker M; Chiarion-Sileni V; Marquez-Rodas I; Grob JJ; Butler MO; Middleton MR; Maio M; Atkinson V; Queirolo P; Gonzalez R; Kudchadkar RR; Smylie M; Meyer N; Mortier L; Atkins MB; Long GV; Bhatia S; Lebbé C; Rutkowski P; Yokota K; Yamazaki N; Kim TM; de Pril V; Sabater J; Qureshi A; Larkin J; Ascierto PA;
    N Engl J Med; 2017 Nov; 377(19):1824-1835. PubMed ID: 28891423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
    Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
    Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
    J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hogg D; Hill A; Márquez-Rodas I; Haanen J; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bastholt L; Rizzo JI; Balogh A; Moshyk A; Hodi FS; Wolchok JD
    N Engl J Med; 2019 Oct; 381(16):1535-1546. PubMed ID: 31562797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    VanderWalde A; Bellasea SL; Kendra KL; Khushalani NI; Campbell KM; Scumpia PO; Kuklinski LF; Collichio F; Sosman JA; Ikeguchi A; Victor AI; Truong TG; Chmielowski B; Portnoy DC; Chen Y; Margolin K; Bane C; Dasanu CA; Johnson DB; Eroglu Z; Chandra S; Medina E; Gonzalez CR; Baselga-Carretero I; Vega-Crespo A; Garcilazo IP; Sharon E; Hu-Lieskovan S; Patel SP; Grossmann KF; Moon J; Wu MC; Ribas A
    Nat Med; 2023 Sep; 29(9):2278-2285. PubMed ID: 37592104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
    Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
    Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
    Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
    Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.